Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

The immunogenicity of cells derived from induced pluripotent stem cells

Cellular & Molecular Immunology volume 11, pages 14–16 (2014)Cite this article

Abstract

With their ability to undergo unlimited self-renewal in culture and to differentiate into all cell types in the body, human embryonic stem cells (hESCs) hold great potential for the treatment of currently incurable diseases. Two hESC-based cell therapies for spinal cord injury and macular degeneration have been advanced into human clinical trials. Despite this rapid progress, one key challenge of hESC-based cell therapy is the allogeneic immune rejection of hESC-derived cells by recipients. This problem could be mitigated by a recent breakthrough in the technology of induced pluripotent stem cells (iPSCs) by nuclear reprogramming of patient-specific somatic cells with defined factors, which could become a renewable source of autologous cells for cell therapy. However, recent studies revealing the abnormal epigenetics, genomic stability and immunogenicity of iPSCs have raised safety concerns over iPSC-based therapy. Recent findings related to the immunogenicity of iPSC derivatives will be summarized in this review.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Article 01 December 2022

Zixuan Zhao, Xinyi Chen, … Hanry Yu

References

  1. Getts DR, Shankar S, Chastain EM, Martin A, Getts MT, Wood K et al. Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy 2011; 3: 853–870.

    Article  CAS  PubMed  Google Scholar 

  2. Felix NJ, Suri A, Salter-Cid L, Nadler SG, Gujrathi S, Corbo M et al. Targeting lymphocyte co-stimulation: from bench to bedside. Autoimmunity 2010; 43: 514–525.

    Article  CAS  PubMed  Google Scholar 

  3. Pearl JI, Lee AS, Leveson-Gower DB, Sun N, Ghosh Z, Lan F et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2010; 8: 309–317.

    Article  Google Scholar 

  4. Rong Z, Wang M, Hu Z, Stradner M, Zhu S, Kong H et al. An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell Jan. 2014; in press.

  5. Turka LA, Wood K, Bluestone JA . Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant 2010; 15: 441–448.

    Article  PubMed  Google Scholar 

  6. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362–368.

    Article  CAS  PubMed  Google Scholar 

  7. Vodyanik MA, Bork JA, Thomson JA, Slukvin II . Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 2005; 105: 617–626.

    Article  CAS  PubMed  Google Scholar 

  8. Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renström J, Lang R et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 2008; 3: 85–98.

    Article  CAS  PubMed  Google Scholar 

  9. Woods NB, Parker AS, Moraghebi R, Lutz MK, Firth AL, Brennand KJ et al. Brief report: efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines. Stem Cell 2011; 29: 1158–1164.

    Article  CAS  Google Scholar 

  10. Zhao T, Zhang ZN, Rong Z, Xu Y . Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212–215.

    Article  CAS  PubMed  Google Scholar 

  11. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013; 494: 100–104.

    Article  CAS  PubMed  Google Scholar 

  12. Andersson G, Denaro M, Johnson K, Morgan P, Sullivan A, Houser S et al. Engraftment of retroviral EGFP-transduced bone marrow in mice prevents rejection of EGFP-transgenic skin grafts. Mol Ther 2003; 8: 385–391.

    Article  CAS  PubMed  Google Scholar 

  13. Andersson G, Illigens BM, Johnson KW, Calderhead D, LeGuern C, Benichou G et al. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood 2003; 101: 4305–4312.

    Article  CAS  PubMed  Google Scholar 

  14. Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS . Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013; 12: 407–412.

    Article  CAS  PubMed  Google Scholar 

  15. Coates PT, Duncan FJ, Colvin BL, Wang Z, Zahorchak AF, Shufesky WJ et al. In vivo-mobilized kidney dendritic cells are functionally immature, subvert alloreactive T-cell responses, and prolong organ allograft survival. Transplantation 2004; 77: 1080–1089.

    Article  PubMed  Google Scholar 

  16. John R, Nelson PJ . Dendritic cells in the kidney. J Am Soc Nephrol 2007; 18: 2628–2635.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from NSFC (81172828, 81373166) to XF.

Author information

Authors and Affiliations

  1. Shenzhen Children's Hospital, Shenzhen, China

    Xuemei Fu

Authors
  1. Xuemei Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xuemei Fu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fu, X. The immunogenicity of cells derived from induced pluripotent stem cells. Cell Mol Immunol 11, 14–16 (2014). https://doi.org/10.1038/cmi.2013.60

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cmi.2013.60

Keywords

This article is cited by

Search

Advanced search

Quick links